Combination of bevacizumab and chemotherapy for platinum-resistant recurrent ovarian cancer: Some observations about the AURELIA trial

Journal of Clinical Oncology

Volumn 32, Issue 31, 2014, Pages 3580-

  Tomao, Federica ^a   Tomao, Silverio ^a   Panici, Pierluigi Benedetti ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; BIOLOGICAL PRODUCT; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADD ON THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; LOW DRUG DOSE; META ANALYSIS (TOPIC); OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); FEMALE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 84911476766     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.6231     Document Type: Letter

References (6)

1. Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302-1308, 2014
2. Huang H, Zheng Y, Zhu J, et al: An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 9:e89960, 2014
3. Ranpura V, Hapani S, Wu S: Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 305:487-494, 2011
4. Lang I, Brodowicz T, Ryvo L, et al: Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: Interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 14:125-133, 2013
5. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
6. Qi WX, Shen Z, Tang LN, et al: Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: A meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol 70:893-906, 2014